From Q2 reportThe Company estimates that the cash flows generated by its operating activities as well as cash availablethrough other sources will be sufficient to finance its operating expenses and capital investment but believes there may be other cost uncertainties pertaining to commissioning and start up of a new plant.
The Company relies upon revenues generated from the sale of active ingredients, the proceeds of public and private offerings of equity securities and debentures, income offerings, and government funding programs to support the Company’s operations.
Hardly such a red siren that there is for sure an equity offering coming.